Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.37 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4774169 | 1.00 | KCNH2 (0.46) | KCNH2AHRCYP1A2GRIK1GRIK2 | |
| SCHEMBL809723 | 0.82 | KCNH2 (0.44) | KCNH2AHRCYP1A2GRIK1GRIK2 | |
| SCHEMBL2093320 | 0.80 | CYP1A2 (0.44) | KCNH2AHRCYP1A2GRIK1GRIK2 | |
| SCHEMBL14303839 | 0.80 | KCNH2 (0.42) | KCNH2AHRCYP1A2GRIK1GRIK2 | |
| SCHEMBL809976 | 0.80 | KCNH2 (0.42) | KCNH2AHRCYP1A2GRIK1GRIK2 | |
| SCHEMBL11353943 | 0.80 | KCNH2 (0.42) | KCNH2AHRCYP1A2GRIK1GRIK2 | |
| SCHEMBL2093324 | 0.80 | CYP1A2 (0.44) | KCNH2AHRCYP1A2GRIK1GRIK2 | |
| SCHEMBL4772837 | 0.80 | NFE2L2 (0.43) | GRIK1GRIK2FBP1DRD2PTGS1 | |
| SCHEMBL2092628 | 0.80 | KCNH2 (0.42) | KCNH2AHRCYP1A2GRIK1GRIK2 | |
| SCHEMBL4772823 | 0.80 | NFE2L2 (0.43) | GRIK1GRIK2FBP1DRD2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1400513-B1 | UNSYMMETRICAL CYCLIC DIAMINE COMPOUND | KOWA CO (JP) | 2008-01-09 | — | — | EP | disclosed |
| EP-1400513-A1 | UNSYMMETRICAL CYCLIC DIAMINE COMPOUND | Kowa Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-6552188-B2 | Inhibit cell adhesion and cell infiltration; useful treating asthma, allergies, rheumatic diseases, arteriosclerosis, and inflammation; 2-(3,4,5-trimethoxyphenyl),4-((4-substituted piperazin-1-yl)methyl)pyridine compounds | KOWA CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| US-20030022887-A1 | Unsymmetrical cyclic diamine compound | KOWA CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022887-A1 | Unsymmetrical cyclic diamine compound | H1-0, DDAH1, AOC1 | KCNH2 127/4885AHR 1878/4885CYP1A2 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.